for a phase three trial of a lung cancer treatment.
While the drug compared well to a competitor on one endpoint, the data for overall survival was "not mature" and pointed toward to the results being not statistically significant, AstraZeneca said in a press release. The trial will continue, according to the company.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »
Recession will take shine off stocks' AI-fueled rally in H2: HSBCUS stocks face a painful rest of 2023 with a recession set to take the shine off the AI-fueled rally, HSBC says
Fonte: BusinessInsider - 🏆 729. / 51 Consulte Mais informação »